Equillium Inc. (EQ) | Rumor.io

Equillium

Attention (50-day avg)0.01%

Attention rank (50-day avg)#610

Bullish sentiment (50-day avg)96%

Price to earnings ratio-4.32

Market capitalization106.5M

Earnings per share-0.09

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-22.4M

Social

What share of all stock conversation is about EQ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.01% +0	0% 0

Dec 22

$EQ has seen a +24% premarket surge, driven by a biotech momentum play and a promising pipeline narrative.
The company's clinical-stage immunology programs, including EQ504 and EQ302, are expected to be key drivers of its growth.
$EQ's stock price is experiencing high volatility, with an RSI of 74.77 and a MACD of 0.0391, indicating a potential sideways or consolidation phase.

Generated by AI

Sentiment

Of the messages about EQ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +10.67	97.85% +12.71
Bearish	—	—	0% -10.67	2.15% -12.71

Bullish· Sep 9

$EQ has a strong management team that values shareholders and has delivered on their promises.
$EQ is experiencing explosive breakout potential with no selling pressure, making it a 52-week high play.
$EQ has a high probability of reaching its upside target of $4.25-$5.00, with a new 52-week high expected to be recorded above $2.35.

Bearish· Aug 11

$EQ's 50 million dollar PIPE deal may have been used to drive up the price of $ABVX, but it could also be a sign of weakness in $EQ.
The company's decision to issue 50 million new shares, with potentially 35 million more shares or pre-funded warrants coming, could lead to massive dilution and a decrease in the stock's value.
$EQ's high trading volume and frequent price drops may be a sign that the stock is being heavily shorted, with some investors dumping large amounts of shares in a short amount of time.

Generated by AI

Topics

Of the messages about EQ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	95.46%
Analysts	—	0%	0%	0.65%
Controversies	—	0%	0%	0.46%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	2.75%
Technical Analysis	—	0%	0%	0.69%

Announcements· Aug 12

Equillium, Inc. has filed a Form 8-K with the SEC, which includes a material agreement, unregistered equity sales, and an investor presentation/press release.
The filing was accepted on August 11, 2025, at 12:35 EDT.
The stock price of Equillium, Inc. has increased by 78.88% as a result of the announcement.

Technical Analysis· Aug 11

$EQ has formed a double bottom on the month chart, indicating a potential bounce.
The stock has shown a 51% pop in price action, with some traders suggesting that bears are trapped above certain levels.
Technical analysis suggests that $EQ needs to break through $1.00 or $0.91 to continue its upward momentum, with some traders looking for a re-entry at $0.97.

Generated by AI

Community

Of the messages about EQ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	82.21%	54.46%
Newcomers	—	0%	17.79%	45.54%

Regulars· Aug 11

Equillium, Inc.'s share price surged 88% pre-market, driven by news of up to $50 million in financing to advance its novel Aryl Hydrocarbon Receptor antagonist EQ504.
The company's AI-powered drug candidate EQ504 has secured major investor backing, with Equillium securing $50 million in funding to support its development.
Equillium's stock price has been a top performer, with a 78% pre-market gain, making it a notable stock to watch in the biotech and autoimmune disease treatment spaces.

Newcomers· Aug 27

$EQ has been Martin's recent long pick, and he has invested a significant amount in his portfolio.
The stock has been in a consolidation phase after a sharp rally and pullback, and its near-term price movement is uncertain.
The company's expansion into renewable energy projects and strategic partnerships has strengthened its market position and boosted investor confidence.

Generated by AI

LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel’s 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT. Members of the Equillium management team will be available to meet with investors who are registered to attend the conference. A

13d agoYahoo! Finance Canada

Equillium at Cantor conference: EQ504 advances as lead ahr program

19d agoInvesting.com

Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Co

27d agoYahoo Finance

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter end

1mo agoYahoo Finance

Also Discussed

Investors talking about EQ also mention

#	Name	Attention
1	MODV - ModivCare Inc.	——
2	BSLK - Bolt Projects Holdings, Inc.	——
3	Tharimmune Inc.THAR	0%new
4	Rave Restaurant Group, Inc.RAVE	0%0
5	electroCore, Inc.ECOR	0%0
6	Scholar Rock Holding Corporation Common StockSRRK	0%new
7	Almonty Industries Inc.ALM	0%+0
8	GMET - VanEck Green Metals ETF	——
9	GrafTech International Ltd.EAF	0%0
10	Equity LifeStyle Properties, Inc.ELS	0%new

Equillium Inc.

Healthcare
Biotechnology

Equillium Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders with high unmet medical need. Its current pipeline centers on immunology programs designed to modulate disease-driving immune pathways, including monoclonal antibody and cytokine-inhibitor approaches aimed at conditions such as graft-versus-host disease, lupus nephritis, ulcerative colitis, alopecia areata, and other immune-mediated diseases. The company’s work spans immuno-inflammatory areas across transplant science, gastroenterology, rheumatology, dermatology, oncology, and related specialty care segments. Equillium Inc. operates as a research-driven biopharmaceutical business, advancing novel therapeutic candidates through clinical development and strategic collaborations to address complex diseases where existing treatment options remain limited. Headquartered in La Jolla, California, Equillium Inc. plays a focused role in the biotechnology market as a developer of targeted immune-modulating medicines.

Website

Location

2223 Avenida De La Playa

La Jolla, CA, 92037

United States

Social

What share of all stock conversation is about EQ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0.01% +0	0% 0

Dec 22

$EQ has seen a +24% premarket surge, driven by a biotech momentum play and a promising pipeline narrative.
The company's clinical-stage immunology programs, including EQ504 and EQ302, are expected to be key drivers of its growth.
$EQ's stock price is experiencing high volatility, with an RSI of 74.77 and a MACD of 0.0391, indicating a potential sideways or consolidation phase.

Generated by AI

Sentiment

Of the messages about EQ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +10.67	97.85% +12.71
Bearish	—	—	0% -10.67	2.15% -12.71

Bullish· Sep 9

$EQ has a strong management team that values shareholders and has delivered on their promises.
$EQ is experiencing explosive breakout potential with no selling pressure, making it a 52-week high play.
$EQ has a high probability of reaching its upside target of $4.25-$5.00, with a new 52-week high expected to be recorded above $2.35.

Bearish· Aug 11

$EQ's 50 million dollar PIPE deal may have been used to drive up the price of $ABVX, but it could also be a sign of weakness in $EQ.
The company's decision to issue 50 million new shares, with potentially 35 million more shares or pre-funded warrants coming, could lead to massive dilution and a decrease in the stock's value.
$EQ's high trading volume and frequent price drops may be a sign that the stock is being heavily shorted, with some investors dumping large amounts of shares in a short amount of time.

Generated by AI

Topics

Of the messages about EQ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	95.46%
Analysts	—	0%	0%	0.65%
Controversies	—	0%	0%	0.46%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	2.75%
Technical Analysis	—	0%	0%	0.69%

Announcements· Aug 12

Equillium, Inc. has filed a Form 8-K with the SEC, which includes a material agreement, unregistered equity sales, and an investor presentation/press release.
The filing was accepted on August 11, 2025, at 12:35 EDT.
The stock price of Equillium, Inc. has increased by 78.88% as a result of the announcement.

Technical Analysis· Aug 11

$EQ has formed a double bottom on the month chart, indicating a potential bounce.
The stock has shown a 51% pop in price action, with some traders suggesting that bears are trapped above certain levels.
Technical analysis suggests that $EQ needs to break through $1.00 or $0.91 to continue its upward momentum, with some traders looking for a re-entry at $0.97.

Generated by AI

Community

Of the messages about EQ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	82.21%	54.46%
Newcomers	—	0%	17.79%	45.54%

Regulars· Aug 11

Equillium, Inc.'s share price surged 88% pre-market, driven by news of up to $50 million in financing to advance its novel Aryl Hydrocarbon Receptor antagonist EQ504.
The company's AI-powered drug candidate EQ504 has secured major investor backing, with Equillium securing $50 million in funding to support its development.
Equillium's stock price has been a top performer, with a 78% pre-market gain, making it a notable stock to watch in the biotech and autoimmune disease treatment spaces.

Newcomers· Aug 27

$EQ has been Martin's recent long pick, and he has invested a significant amount in his portfolio.
The stock has been in a consolidation phase after a sharp rally and pullback, and its near-term price movement is uncertain.
The company's expansion into renewable energy projects and strategic partnerships has strengthened its market position and boosted investor confidence.

Generated by AI

Equillium

Social

Dec 22

Bullish· Sep 9

Bearish· Aug 11

Announcements· Aug 12

Technical Analysis· Aug 11

Regulars· Aug 11

Newcomers· Aug 27

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium at Stifel 2026 Virtual Immunology and Inflammation Forum: pipeline advances

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

Equillium at Cantor conference: EQ504 advances as lead ahr program

Equillium to Participate in Upcoming Investor Conferences

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Also Discussed

Equillium Inc.

Company Information

Location

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium at Stifel 2026 Virtual Immunology and Inflammation Forum: pipeline advances

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

Equillium at Cantor conference: EQ504 advances as lead ahr program

Equillium to Participate in Upcoming Investor Conferences

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Also Discussed

Social

Dec 22

Bullish· Sep 9

Bearish· Aug 11

Announcements· Aug 12

Technical Analysis· Aug 11

Regulars· Aug 11

Newcomers· Aug 27